Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone386-462-2204
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$24.19 million
Profitability
Miscellaneous
Employees78
Next Earnings Date9/26/2019 (Confirmed)
OptionableOptionable
Applied Genetic Technologies (NASDAQ:AGTC) Frequently Asked Questions
What is Applied Genetic Technologies' stock symbol?
Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."
How were Applied Genetic Technologies' earnings last quarter?
Applied Genetic Technologies Corp (NASDAQ:AGTC) announced its quarterly earnings data on Monday, September, 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by $0.20. The biotechnology company earned $5.42 million during the quarter, compared to the consensus estimate of $6.87 million. Applied Genetic Technologies had a net margin of 4.06% and a return on equity of 2.22%. View Applied Genetic Technologies' Earnings History.
When is Applied Genetic Technologies' next earnings date?
How can I listen to Applied Genetic Technologies' earnings call?
Applied Genetic Technologies will be holding an earnings conference call on Thursday, September 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for AGTC?
6 equities research analysts have issued twelve-month price targets for Applied Genetic Technologies' shares. Their forecasts range from $5.00 to $15.00. On average, they expect Applied Genetic Technologies' stock price to reach $10.5833 in the next year. This suggests a possible upside of 209.5% from the stock's current price. View Analyst Price Targets for Applied Genetic Technologies.
What is the consensus analysts' recommendation for Applied Genetic Technologies?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Applied Genetic Technologies.
What are Wall Street analysts saying about Applied Genetic Technologies stock?
Here are some recent quotes from research analysts about Applied Genetic Technologies stock:
- 1. Chardan Capital analysts commented, "We now upgrade AGTC to the opportunity represented by a company: (1) now trading at 64% of 30 March 2019 cash, and (2) with important phase I/II data through 1H20 on 3 different programs (ACHM-A3, ACHM-B3, XLRP). We continue to flag the delays AGTC has had over the years in reporting datasets in achromatopsia A3 (ACHM-A3), achromatopsia X- linked retinitis pigmentosa (XLRP). The delays occurred as innovative companies like MeiraGTx (Buy, a Therapeutics (acquired by unrated Biogen) made progress with competing inherited retinal disease franchises (see research below). Despite the AGTC delays, we note that good science sometimes takes time to develop; and, industry participants recognize the soundness of AGTC’s science and broader capabilities, even if execution has been slow." (9/3/2019)
- 2. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (8/12/2019)
- 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating $12 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Currently the ACHM programs contribute 55% to our valuation, with the remaining 45% coming from XLRP. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (7/25/2019)
Has Applied Genetic Technologies been receiving favorable news coverage?
News coverage about AGTC stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Applied Genetic Technologies earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Applied Genetic Technologies.
Are investors shorting Applied Genetic Technologies?
Applied Genetic Technologies saw a increase in short interest in August. As of August 31st, there was short interest totalling 47,700 shares, an increase of 44.5% from the July 31st total of 33,000 shares. Based on an average trading volume of 70,500 shares, the short-interest ratio is presently 0.7 days. Currently, 0.4% of the shares of the stock are short sold. View Applied Genetic Technologies' Current Options Chain.
Who are some of Applied Genetic Technologies' key competitors?
Some companies that are related to Applied Genetic Technologies include PDL BioPharma (PDLI), Sutro Biopharma (STRO), LogicBio Therapeutics (LOGC), Compugen (CGEN), X4 Pharmaceuticals (XFOR), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Dyadic International (DYAI), Novavax (NVAX), Oncobiologics (ONS), Axcella Health (AXLA), Aptose Biosciences (APTO), Nantkwest (NK), Windtree Therapeutics (WINT) and Jounce Therapeutics (JNCE).
What other stocks do shareholders of Applied Genetic Technologies own?
Who are Applied Genetic Technologies' key executives?
Applied Genetic Technologies' management team includes the folowing people:
- Ms. Susan B. Washer, Pres, CEO & Director (Age 58)
- Mr. William A. Sullivan, Chief Financial Officer (Age 48)
- Dr. Matthew Feinsod, Interim Chief Medical Officer (Age 48)
- Dr. Nicholas Muzyczka, Co-Founder
- Dr. Barry J. Byrne, Co-Founder
Who are Applied Genetic Technologies' major shareholders?
Applied Genetic Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.27%), BlackRock Inc. (1.71%), Price T Rowe Associates Inc. MD (1.44%), Colony Group LLC (0.89%), Jacobs Levy Equity Management Inc. (0.45%) and D. E. Shaw & Co. Inc. (0.32%). Company insiders that own Applied Genetic Technologies stock include Susan B Washer, William A Sullivan and William Aliski. View Institutional Ownership Trends for Applied Genetic Technologies.
Which major investors are selling Applied Genetic Technologies stock?
Which major investors are buying Applied Genetic Technologies stock?
AGTC stock was purchased by a variety of institutional investors in the last quarter, including Colony Group LLC, Renaissance Technologies LLC, BlackRock Inc., Wells Fargo & Company MN, Jacobs Levy Equity Management Inc., JPMorgan Chase & Co. and D. E. Shaw & Co. Inc.. Company insiders that have bought Applied Genetic Technologies stock in the last two years include Susan B Washer, William A Sullivan and William Aliski. View Insider Buying and Selling for Applied Genetic Technologies.
How do I buy shares of Applied Genetic Technologies?
Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Applied Genetic Technologies' stock price today?
One share of AGTC stock can currently be purchased for approximately $3.42.
How big of a company is Applied Genetic Technologies?
Applied Genetic Technologies has a market capitalization of $62.14 million and generates $24.19 million in revenue each year. The biotechnology company earns $-21,300,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis. Applied Genetic Technologies employs 78 workers across the globe.View Additional Information About Applied Genetic Technologies.
What is Applied Genetic Technologies' official website?
How can I contact Applied Genetic Technologies?
Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.
MarketBeat Community Rating for Applied Genetic Technologies (NASDAQ AGTC)
MarketBeat's community ratings are surveys of what our community members think about Applied Genetic Technologies and other stocks. Vote "Outperform" if you believe AGTC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGTC will underperform the S&P 500 over the long term. You may vote once every thirty days.
